Even though Pfizer is a good asset to invest during 2021, it is not considered one of the 10th values to the future. The current prevision is around $3.10 per share, a bit lower than what was expected last 2020. This is due to the fact that some studies from Ibrance about breast cancer drugs were not positive. Thus, some issues related to the cold storage the new Pfizer’s vaccines requires makes more difficult its index positions. However, one of the biggest assets to this year to the company is still the vaccine; the prevision is an annual earning of 10% during the next years. Therefore, next June Pfizer will launch a new 20-valent pneumococcal vaccines, that looks a huge asset opportunity. The global vaccine previsions is around 1,300 millions dose, around 21,400 millions of euros. These numbers are only about vaccine revenues. We should add the rest of projects Pfizer is involved to realize it is a good investment.